B-Cell Acute Lymphoblastic Leukemia

NCI Definition: The most frequent type of acute lymphoblastic leukemia. Approximately 75% of cases occur in children under six years of age. This is a good prognosis leukemia. In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%. Approximately 80% of children appear to be cured. In the adult age group the complete remission rate is 60-85%. (WHO, 2001) [1]

Clinical Trials

View Clinical Trials for B-Cell Acute Lymphoblastic Leukemia

There are 126 clinical trials for B-cell acute lymphoblastic leukemia, of which 107 are open and 19 are completed or closed. Of the trials that contain B-cell acute lymphoblastic leukemia as an inclusion criterion, 7 are early phase 1 (7 open), 44 are phase 1 (37 open), 22 are phase 1/phase 2 (20 open), 38 are phase 2 (29 open), 3 are phase 2/phase 3 (3 open), 8 are phase 3 (7 open), 2 are phase 4 (2 open), and 2 are no phase specified (2 open).

CD19, CD22, and BCR-ABL1 are the most frequent gene inclusion criteria for B-cell acute lymphoblastic leukemia clinical trials [3].

Trials Investigating B-Cell Acute Lymphoblastic Leukemia by Gene and Recruiting Status

Cyclophosphamide, fludarabine, and blinatumomab are the most common interventions in B-cell acute lymphoblastic leukemia clinical trials.

Drugs Being Investigated in B-Cell Acute Lymphoblastic Leukemia Trials by Recruiting Status

Significant Genes in B-Cell Acute Lymphoblastic Leukemia

ABL1 +

ABL1 is an inclusion eligibility criterion in 20 clinical trials for B-cell acute lymphoblastic leukemia, of which 16 are open and 4 are closed. Of the trials that contain ABL1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (6 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [3].

ABL2 +

ABL2 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain ABL2 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 3 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain AFF1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

ASXL1 +

ASXL1 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain ASXL1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BCL2 +

BCL2 is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

BCL6 +

BCL6 is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 17 clinical trials for B-cell acute lymphoblastic leukemia, of which 14 are open and 3 are closed. Of the trials that contain BCR status and B-cell acute lymphoblastic leukemia as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [3].

CBL +

CBL is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBL status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CEP72 +

CEP72 is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CEP72 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CRLF2 +

CRLF2 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain CRLF2 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

DEK +

DEK is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain DEK status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain ELL status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

EPOR +

EPOR is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain EPOR status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

FGFR1 +

FGFR1 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain FGFR1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

FGFR2 +

FGFR2 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain FGFR2 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

FGFR3 +

FGFR3 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain FGFR3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

FGFR4 +

FGFR4 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain FGFR4 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 8 clinical trials for B-cell acute lymphoblastic leukemia, of which 6 are open and 2 are closed. Of the trials that contain FLT3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [3].

HLF +

HLF is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain HLF status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

IGH +

IGH is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IGH status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].

IGK +

IGK is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IGK status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].

IGL +

IGL is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IGL status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].

IKZF1 +

IKZF1 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IKZF1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

IL7R +

IL7R is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain IL7R status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

JAK1 +

JAK1 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain JAK1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

JAK2 +

JAK2 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain JAK2 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

JAK3 +

JAK3 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain JAK3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 8 clinical trials for B-cell acute lymphoblastic leukemia, of which 8 are open and 0 are closed. Of the trials that contain KMT2A status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 2 are phase 3 (2 open) [3].

KRAS +

KRAS is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

LYN +

LYN is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain LYN status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

MECOM +

MECOM is an inclusion eligibility criterion in 3 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 1 is closed. Of the trials that contain MECOM status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MLF1 +

MLF1 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain MLF1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT10 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 3 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain MLLT3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT4 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MYC +

MYC is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

NPM1 +

NPM1 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain NPM1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

NRAS +

NRAS is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain NRIP3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

NTRK1 +

NTRK1 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain NTRK1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

NTRK2 +

NTRK2 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain NTRK2 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

NTRK3 +

NTRK3 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain NTRK3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain NUP214 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain PDGFRA status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

PDGFRB +

PDGFRB is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain PDGFRB status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

PTPN11 +

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTPN11 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 3 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 1 is closed. Of the trials that contain RPN1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RUNX1 +

RUNX1 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

SH2B3 +

SH2B3 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain SH2B3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

TCF3 +

TCF3 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain TCF3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

TP53 +

TP53 is an inclusion eligibility criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

TRA +

TRA is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRA status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

TRB +

TRB is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRB status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

TRD +

TRD is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRD status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

TRG +

TRG is an inclusion eligibility criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRG status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

TYK2 +

TYK2 is an inclusion eligibility criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain TYK2 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [3].

Disease Details

Synonyms

B-Cell Precursor Type Acute Leukemia, B-cell precursor acute lymphoblastic leukemia, Bone marrow leukemia B cell acute (B-ALL), Precursor B-Lymphoblastic Leukemia, B-ALL

Parent(s)

B-Cell Lymphoblastic Leukemia/Lymphoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

B-Cell Acute Lymphoblastic Leukemia

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in B-Cell Acute Lymphoblastic Leukemia

Disease Details

References

About

Molecular Medicine

Content Types